Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database
International Immunopharmacology · 2026-01 · 168 · 115751
DOI: 10.1016/j.intimp.2025.115751 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-01. Verfasst von Chengze Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; West China Medical School of Sichuan U…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing, Complement Inactivating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Sichuan University West China Hospital.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; West China Medical School of Sichuan University, Chengdu, Sichuan, China; Kidney Transplantation Center, Wes…
- Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Kidney Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Organ Trans…
Förderung
- Sichuan University West China Hospital
Zitieren
APA
Liang, C., Yin, S., Zhang, H., Song, T., & Lin, T. (2026). Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database. International Immunopharmacology, 168, 115751. https://doi.org/10.1016/j.intimp.2025.115751
Vancouver
Liang C, Yin S, Zhang H, Song T, Lin T. Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database. International Immunopharmacology. 2026;168:115751. doi:10.1016/j.intimp.2025.115751
BibTeX
@article{Liang2026,
author = {Liang, Chengze and Yin, Saifu and Zhang, Hao and Song, Turun and Lin, Tao},
title = {Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database},
journal = {International Immunopharmacology},
year = {2026},
volume = {168},
pages = {115751},
doi = {10.1016/j.intimp.2025.115751}
}
EUVIMED